Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibrx Biosciences, Inc.INBX · Entity 4576 | Director | June 03, 2026 | September 18, 2026 |
| KOREA FUND INCKF · Entity 6087 | Affiliated Person | April 01, 2013 | December 02, 2016 |
| Virtus Convertible & Income 2024 Target Term FundCBH · Entity 90218 | Portfolio Manager | June 27, 2017 | June 30, 2017 |
| Virtus Equity & Convertible Income FundNIE · Entity 5206 | Affiliated Person | August 11, 2020 | August 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibrx Biosciences, Inc.
Report date June 03, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.22 · Expires 2036-06-03 | Direct | 10,000 |
Reported balance
After 2026-06-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.
KOREA FUND INC
Report date April 01, 2013 · Filed December 02, 2016
This filing explicitly reported no securities owned.
Virtus Convertible & Income 2024 Target Term Fund
Report date June 27, 2017 · Filed June 30, 2017
This filing explicitly reported no securities owned.
Virtus Equity & Convertible Income Fund
Report date August 11, 2020 · Filed August 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-08-11 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2020-08-11 · Sale · Disposed 10,000 · Balance 10,000 Row 2 · 2020-08-11 · Sale · Disposed 100 · Balance 9,900 Row 3 · 2020-08-11 · Sale · Disposed 100 · Balance 9,800 Row 4 · 2020-08-11 · Sale · Disposed 800 · Balance 9,000 Row 5 · 2020-08-11 · Sale · Disposed 1,791 · Balance 7,209 Row 6 · 2020-08-11 · Sale · Disposed 709 · Balance 6,500 Row 7 · 2020-08-11 · Sale · Disposed 1,900 · Balance 4,600 Row 8 · 2020-08-11 · Sale · Disposed 600 · Balance 4,000 Row 9 · 2020-08-11 · Sale · Disposed 4,000 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inhibrx, Inc.
Report date May 30, 2024 · Filed May 30, 2024
Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Forsyth Family Trust Dated July 20, 2001 | 0 |
Reported balance
After 2024-05-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-30 · Disposition to issuer · Disposed 598,257 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2028-11-26 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-30 · Disposition to issuer · Disposed 17,259 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.78 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F8: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.
F3: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.
F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter
F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option.
F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F8: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 8, 2026 20:26 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,500 | $114.65 | $286,617.25 |
DisclosureSEC source: 0001240801-26-000004 · wk-form4_1788899160.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 227,064 F1 · price: The shares were purchased in multiple transactions at prices ranging from $114.36 to $114.689 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| June 03, 2026 Filed Sep 18, 2026 20:26 UTC Amendment | Inhibrx Biosciences, Inc. INBX · Entity 4576 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $95.22 | $0.00 |
DisclosureSEC source: 0001240801-26-000006 · wk-form4a_1789763184.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 21:28 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $95.22 | $0.00 |
DisclosureSEC source: 0001240801-26-000002 · wk-form4_1780608533.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:24 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0002007919-25-000066 · wk-form4_1748550291.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-28 F1 · derivative.exercise_date: This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:26 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 59,812 | $14.07 | $841,554.84 |
DisclosureSEC source: 0002007919-24-000040 · wk-form4_1724704006.xml · nonDerivative · entry 2 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 224,564 F3 · price: The shares were purchased in multiple transactions at prices ranging from $13.48 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 20:26 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 15,188 | $12.89 | $195,773.32 |
DisclosureSEC source: 0002007919-24-000040 · wk-form4_1724704006.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 164,752 F1 · price: The shares were purchased in multiple transactions at prices ranging from $12.80 to $13.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $24.78 | Not disclosed |
DisclosureSEC source: 0000950142-24-001498 · es240484807_4-forsyth.xml · derivative · entry 5 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-07 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F8 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $12.57 | Not disclosed |
DisclosureSEC source: 0000950142-24-001498 · es240484807_4-forsyth.xml · derivative · entry 4 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F7 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $23.03 | Not disclosed |
DisclosureSEC source: 0000950142-24-001498 · es240484807_4-forsyth.xml · derivative · entry 3 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 17,259 | Not disclosed Strike: $10.52 | Not disclosed |
DisclosureSEC source: 0000950142-24-001498 · es240484807_4-forsyth.xml · derivative · entry 2 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,259 shares Expires 2028-11-26 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F4 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerCommon Stock | 598,257 | $30.00 | $17,947,710.00 |
DisclosureSEC source: 0000950142-24-001498 · es240484807_4-forsyth.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| May 30, 2024 Filed May 30, 2024 22:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0000950142-24-001491 · es240484861_4-forsyth.xml · derivative · entry 2 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-30 F3 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. F4 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 22:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantCommon Stock | 149,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001491 · es240484861_4-forsyth.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 149,564 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F2 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:12 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0001739614-23-000056 · wk-form4_1685477509.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:46 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001739614-22-000067 · wf-form4_165359798699725.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,259 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.78 | $0.00 |
DisclosureSEC source: 0001739614-21-000072 · wf-form4_162318730693101.xml · derivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,259 Underlying: Common Stock · 15,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: (1) Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 20:24 UTC | Inhibrx, Inc. INBX · Entity 90351 | ConversionSeries Mezzanine 2 Preferred Stock · Derivative | 143,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012983 · wf-form4_159804146902868.xml · derivative · entry 2 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 0 Underlying: Common Stock · 82,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the issuer's certificate of incorporation in effect immediately prior to the closing of the issuer's initial public offering. The preferred stock had no expiration date. F2 · derivative.exercise_date: The amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the issuer's certificate of incorporation in effect immediately prior to the closing of the issuer's initial public offering. The preferred stock had no expiration date. F2 · derivative.expiration_date: The amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the issuer's certificate of incorporation in effect immediately prior to the closing of the issuer's initial public offering. The preferred stock had no expiration date. F1 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 20:24 UTC | Inhibrx, Inc. INBX · Entity 90351 | ConversionCommon Stock | 82,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012983 · wf-form4_159804146902868.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Forsyth Family Trust Dated July 20, 2001 Disclosed balance after: 598,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 4,000 | $24.63 | $98,520.00 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 9 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 600 | $24.64 | $14,784.00 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 8 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 1,900 | $24.64 | $46,816.19 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 7 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 709 | $24.66 | $17,483.94 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 6 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 1,791 | $24.70 | $44,241.28 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 5 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 800 | $24.66 | $19,729.12 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 4 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 100 | $24.67 | $2,467.20 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 3 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 100 | $24.69 | $2,469.00 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 2 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 12:34 UTC | Virtus Equity & Convertible Income Fund NIE · Entity 5206 | SaleCommon Stock | 10,000 | $24.68 | $246,760.00 |
DisclosureSEC source: 0001209191-20-046509 · doc4.xml · nonDerivative · entry 1 FORSYTH DOUGLAS · CIK 0001240801 · Affiliated Person 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.